Other Events ·
Lunai Bioworks asks Nasdaq to suspend trading over alleged market manipulation
LNAILunai Bioworks Inc.
On October 9, 2026, Lunai Bioworks submitted a formal request to the Nasdaq Stock Market to immediately suspend trading in its common stock. The company cites court-ordered discovery records from pending litigation against Seven Points Capital LLC that allege substantial short selling, locate deficiencies, and failures to deliver. Lunai argues these activities indicate an unfair market and seeks urgent review by Nasdaq and FINRA before a decision is made. Trading remains active as no ruling has been issued yet. The company operates in the biotechnology sector.